An overview of Phage–Polymyxin Interactions Against Multidrug-Resistant Pseudomonas aeruginosa
Year: 2026
Type: article
Abstract: Multidrug-resistant (MDR) Pseudomonas aeruginosa causes difficult-to-treat acute and chronic infections, and colistin remains a salvage option limited by nephrotoxicity, heteroresistance and uncertain target-site exposure. Lytic bacteriophages are an independent antibacterial modality, but colistin acts on lipopolysaccharide (LPS), which is also a phage receptor, so the two agents may interact in either direction. This focused narrative review appraises evidence on phage–colistin combinations, emphasising reports from 2024 to October 2026, using four evidence tiers: direct phage–colistin studies, phage studies with other antibiotics, clinical phage studies with background antibiotics, and formulation and pharmacokinetic/pharmacodynamic (PK/PD) literature. Direct in vitro data are heterogeneous: synergy or additivity with colistin was reported for a subset of metallo-β-lactamase-producing isolates, colistin sensitisation occurred in nearly all of nine strains in a 2026 pharmacodynamic study, and phage-first application strengthened synergy for one phage, whereas earlier work showed that colistin can suppress phage lysis and progeny production. Human studies of nebulised and personalised phage therapy support feasibility and safety but cannot attribute effects to colistin because background antibiotics were used. Recovery of infectious phage after storage and aerosolisation emerged as a determinant of potency. We propose critical quality attributes, a PK/PD structure with an explicit interaction term, a six-stage roadmap with go/no-go gates and a minimum reporting checklist. Phage–colistin therapy should be developed as an isolate-matched investigational intervention and should not be assumed to permit lower colistin exposure or improved outcomes without direct validation.
Language: English
Subfield: Virology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W7236416182
